Skip to main content

Valion Bio, Inc.

corporate_fare Company Profile

Valion Bio, Inc.

VBIO·NASDAQ·Life Sciences·CIK 0001787740

Tivic Health Systems, Inc. is a late-stage biopharmaceutical company focused on developing Entolimod, a recombinant TLR5 agonist. Entolimod is being developed as a medical countermeasure for Acute Radiation Syndrome (ARS) and its related conditions, and as an additional therapy for oncology indications like neutropenia. During fiscal year 2025, Tivic Health underwent a significant strategic change, shifting from a diversified bioelectronic medical device company to a biopharmaceutical company centered on its TLR5 agonist franchise. In February 2025, Tivic secured worldwide exclusive license rights and options for Entolimod and its second-generation compound, Entolasta. In December 2025, the company established Velocity Bioworks, a subsidiary contract development and manufacturing organization (CDMO) intended to support both Tivic and selected third-party clients. Concurrently, Tivic exited the consumer healthtech business and paused its prescription bioelectronic product development to fully dedicate resources to Entolimod. The company is now focused on two main areas: advancing Entolimod and Entolasta through regulatory approval for acute radiation syndrome and into government procurement, and expanding Entolimod's uses to include oncology-related conditions such as neutropenia, thrombocytopenia, and general and specific mucositis. Tivic's common stock trades on The Nasdaq Capital Market under the symbol "TIVC." The company is headquartered in San Antonio, TX, and operates a Current Good Manufacturing Practice (CGMP)-compatible biomanufacturing facility in San Antonio, Texas, through Velocity Bioworks. It uses a hybrid remote and on-site operational model.

Valion Bio, Inc. (NASDAQ:VBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for VBIO at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Valion Bio Q2 Loss Widens to $7.1M; Cash Drops to $2.1M, Going Concern Doubt Reiterated
  • Activist 3i Proposes $9M Rescue Financing and Board Overhaul at Valion Bio
  • Activist Investor 3i, LP Demands Immediate Removal of Valion Bio CEO
  • Valion Bio Launches $15M Offering at $0.51/Unit, Deeply Dilutive for Micro-Cap
  • Valion Bio Files for Up to $15M Best-Efforts Offering at $0.51/Unit Amid Going Concern

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$8.88M
Op. Cash Flow
-$7M
Free Cash Flow
-$7.04M
Operating Income
-$7.9M
Cash & Equivalents
$12.64M
Total Debt
$6.45M
Debt / Equity
0.38×
Shares Outstanding
2.53M sh
Source: 10-K · filed 2026-03-30 · accession 0001437749-26-010343
$0.473 -1.58% today
52-week range · as of 2026-11-16 $0.4715 – $67.5
Market cap
$1.04M
Volume
137.7K (0.1× avg)
3-mo avg 1.2M
Live data · 2026-11-22 12:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VBIO - Filings & News (Page 2)

VBIO
Aug 14, 2026, 5:30 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.1794
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Aug 11, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.3264
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Aug 03, 2026, 7:01 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $0.3162
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Jul 17, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.480
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Jul 17, 2026, 4:01 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $0.5105
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Jul 14, 2026, 7:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5589
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Jul 07, 2026, 5:06 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.5125
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Jun 18, 2026, 9:19 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5411
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
Jun 03, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.6799
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
May 14, 2026, 5:31 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.02
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
May 14, 2026, 5:29 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.00
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
May 14, 2026, 4:36 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.02
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
VBIO
May 05, 2026, 8:33 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.09
Real-time Price: $0.473 info
Change: Reverse Stock Split info
Market Cap: $1.036M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets